1. Signaling Pathways
  2. Immunology/Inflammation
  3. AP-1
  4. c-Jun Isoform

c-Jun

c-Jun, a basic leucine zipper transcription factor, regulates gene expression in response to multiple extracellular signals[1]. It is a central component of the activator protein-1 (AP-1) complex, mediating cellular proliferation, differentiation, and stress responses[2][3]. Mechanistically, c-Jun is primarily activated by phosphorylation through the c-Jun N-terminal kinase (JNK) pathway, linking stress signals to transcriptional outputs[3][4]. Isoform-specific functions of JNK1, JNK2, and JNK3 modulate c-Jun activity in tissue- and cell-specific contexts, influencing apoptosis, inflammation, and neuroplasticity[1][5][6]. In disease models, c-Jun contributes to pathological angiogenesis, rheumatoid arthritis, and neurodegeneration, where its inhibition reduces endothelial proliferation, metalloproteinase expression, and neuronal apoptosis[7][8][9][10][11][12]. Compared with related Jun-family members, c-Jun exhibits distinct phosphorylation patterns and transcriptional targets, enabling isoform-specific experimental interventions[6][13]. Pharmacological inhibitors targeting JNK or c-Jun itself, such as SP600125 or DNAzymes, demonstrate utility in blocking pro-apoptotic signaling, reducing inflammation, and modulating angiogenic pathways, supporting their research and therapeutic application[7][8][10][12]. In cancer and viral models, c-Jun interacts with oncogenic pathways, including Bcl-2/Bcl-xL upregulation and FGF-2-mediated proliferation, highlighting its role in cell survival and transcriptional regulation[2][14]. Collectively, c-Jun integrates stress, mitogenic, and inflammatory signals, serving as a critical target for isoform-specific modulation in experimental and disease contexts[1][3][6][7].

References:

c-Jun Related Products (1):

Cat. No. Product Name Effect Purity
  • HY-168895
    c-Fos-IN-1
    Inhibitor
    c-Fos-IN-1 (Compound P16) is a c-Jun inhibitor, and decreases mRNA levels and protein levels of c-Fos. c-Fos-IN-1 also inhibits the phosphorylation activity of ERK and the transcriptional activity of AP-1. c-Fos-IN-1 shows anticancer activity by inhibiting ERK/c-Fos/Jun pathway. c-Fos-IN-1 inhibits the proliferation and migration of gastric cancer cells (IC50: 2.31 μM for MGC-803 cell). c-Fos-IN-1 arrests cell cycle at G2/M phase and induces cancer cell apoptosis. c-Fos-IN-1 inhibits gastric cancer tumor growth.